Association of clear cell carcinoma of the endometrium with a high rate of venous thromboembolism

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 54, Issue 3, 2009, Pages 133-138

  Lee, Lisa ^a   Garrett, Leslie ^a   Lee, Hang ^a   Oliva, Esther ^a   Horowitz, Neil ^a   Duska, Linda R ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Clear cell carcinoma; Endometrial cancer; Venous thromboembolism

Indexed keywords

HEPARIN;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CEREBROVASCULAR ACCIDENT; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOMETRIUM CARCINOMA; FEMALE; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; LUNG EMBOLISM; LYMPHADENECTOMY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SALPINGOOOPHORECTOMY; SURVIVAL; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); ENDOMETRIAL NEOPLASMS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PRIMARY PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 63749123334     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Gof f BA, Sainz de la Cuesta R, Muntz HG, et al: Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996;60:412-417
2. Recio FO, Piver MS, Hempling RE, et al: Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 1996;78:2157-2163
3. Kennedy AW, Biscotti CV, Hart WR, et al: Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989;32:342-349
4. Bergqvist D, Agnelli G, Cohen AT, et al: Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975-980
5. Murphy KT, Rotmensch J, Yamada SD, et al: Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: Implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2003;55:1272-1276
6. Zorn KK, Bonome T, Gangi L, et al: Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005;11:6422-6430
7. Matsuura Y, Robertson G, Marsden DE, et al: Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol 2007;104:406-410
8. Uno K, Homma S, Satoh T, et al: Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 2007;96:290-295
9. Sorensen HT, Mellemkjaer L, Olsen JH, et al: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-1850
10. Chew HK, Wun T, Harvey D, et al: Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458-464
11. Chew HK, Wun T, Harvey DJ, et al: Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007;25:70-76
12. Morgan MA, Iyengar TD, Napiorkowski BE, et al: The clinical course of deep vein thrombosis in patients with gynecologic cancer. Gynecol Oncol 2002;84:67-71
13. Meyer G, Marjanovic Z, Valcke J, et al: Comparison of low- molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Intern Med 2002;162:1729-1735
14. Hutten BA, Prins MH, Gent M, et al: Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis. J Clin Oncol 2000;18:3078-3083
15. Gitter MJ, Jaeger TM, Petterson TM, et al: Bleeding and thromboembolism during anticoagulant therapy: A population- based study in Rochester, Minnesota. Mayo Clin Proc 1995; 70:725-733
16. Palareti G, Legnani C, Lee A, et al: A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000;84:805-810
17. Prandoni P, Lensing AW, Piccioli A, et al: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488
18. Lee AY, Rickles FR, Julian JA, et al: Randomized comparison of low molecular weight heparin and Coumadin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-2129
19. Sallah S, Husain A, Sigounas V, et al: Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res 2004;10:7238-7243
20. Lee AY, Levine MN, Baker RI, et al: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153
21. Kakkar AK, Levine MN, Kadziola Z, et al: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004;22:1944-1948
22. Klerk CP, Smorenburg SM, Otten HM, et al: The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2135